Tagged with clinical tria

Pharma György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of budget constraints as well his work founding the Hungarian Society of Clinical Oncology. As an introduction to our readers could…

Pharma The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute of Medicinal Chemistry (SRIMC) in Hungary plays in the group’s overall R&D activities. He also elaborates on the crucial importance…

Pharma While the Italian clinical research community works to an excellent standard of quality, and is relatively competitive in terms of costs, regulatory differences with the rest of Europe pose significant challenges. Mariapia Cirenei and Stefano Marini, president of AICRO and EUCROF respectively, discuss these current challenges, and how the new…

Pharma Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease profiles—these seem to be the fundamentals truly driving growth in South Africa’s clinical trial industry. However, without the presence of proper mechanisms to arbitrate between regulators and researchers, the sustained growth of this industry may very…

Pharma Peter Schoevers, CEO and co-founder of Julius Clinical, explains how this innovative and thriving organization allies the academic strength of an ARO with the business-oriented leadership of a CRO. Julius Clinical aims to become the partner of choice for the pharmaceutical industry by strengthening clinical trial credibility, enhancing its quality…

Pharma Click here to read more articles and interviews from Peru, and to download the latest free pharma report on the country. 

pharma Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed by the increasingly high cost of innovative drugs on the healthcare budget. Prof. Smits highlights the benefits that could be…

Pharma ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes – Novo Nordisk, Leo, Lundbeck and ALK – are good examples of the best pupils in class when it comes…

pharma Harnessing the power of big data and the Internet, myTomorrows is working to help patients in need to access treatments that would otherwise not be available outside of a clinical trial. CEO Ronald Brus discusses the workings of this unique and disruptive company. As an introduction, given your wealth of experience in…

Pharma Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French clinical research environment as well as his personal motivations for working in a rapidly growing biotech company. ARIAD’s niche is…

pharma Jan Smeitink, CEO of Khondrion, a young biotech company designing highly innovative solutions for people suffering from mitochondrial diseases, provides an overview of the latest developments regarding the company’s lead compound and explains how its talented team and strategic partnership with the Radboud University Medical Centre will help Khondrion to…

pharma The founder and managing director of LT Clinical Research, one of the first wholly black-owned South African CRO, reveals how South Africa is a very conducive environment for CROs, with a diverse patient population, a well-established regulatory framework and a currency that compares well to other African currencies; why the…